Documentary Genealogy — Predecessors to Khavinson's Peptide Bioregulator Doctrine

Mapping the Soviet tissue-extract / peptide therapy lineage that Vladimir Khatskelevich Khavinson (1946–2024) inherited, transformed and rebranded at the Saint Petersburg Institute of Bioregulation and Gerontology.

0. Anchor: who V.Kh. Khavinson is, and what he inherited

Vladimir Khatskelevich Khavinson (Владимир Хацкелевич Хавинсон) was born on 27 November 1946 in Cottbus, in what was then the Soviet occupation zone of Germany, and died on 6 January 2024 in St. Petersburg. He held the rank of Colonel of Medical Service in the USSR/Russian armed forces, ran the Saint Petersburg Institute of Bioregulation and Gerontology as its director, and chaired gerontology at the North-Western State Medical University. Over four decades his laboratory turned a vague Soviet doctrine about tissue extracts into a patented industry. The bioregulator programme produced six Russian-registered medicines — Thymalin, Epithalamin, Cortexin, Prostatilen (sold as Samprost and Vitaprost), Retinalamin, and Thymogen — and sixty-four peptide dietary supplements. Out of the tissue extracts came fifteen-plus defined synthetic short peptides: Epitalon (the AEDG tetrapeptide), Vilon, Cortagen, Cartalax, Livagen, Pinealon, Vesugen, and others. The portfolio is locked down by 196 patents across the United States, Canada, Australia, the European Union, Japan, Korea, and Israel.^[1]

The intellectual chain runs through the S.M. Kirov Military Medical Academy in Leningrad, where Khavinson trained. In the 2013 interview with biogerontologist Suresh Rattan he put it plainly: while a student there he "felt himself like a grand-student of I.P. Pavlov."^[2] That claim — a deliberate, retrospective positioning inside a Russian physiological canon — is what this document maps. Khavinson's mechanistic vocabulary also leans heavily on Hans Selye's stress model, but the operating doctrine he is *intellectually situated inside* is the older Russian tissue-extract / organotherapy / nervism / trophism current: Pavlov → Speransky → Bogomolets → Filatov → Asatiani → Khavinson and V.G. Morozov.

The trajectory is straightforward once you accept the founding assumption. In 1971, as a young military physician, Khavinson began the peptide-extraction work at the Kirov Academy. He returned in 1976 as a bench scientist and in 1982 founded the special laboratory on bioregulation. Morozov, his long-time collaborator, sits in the same lineage — together they carried the Filatov biogenic-stimulators programme into a molecular era. The history that follows is the substrate they stood on.

1. Bogomolets, Alexander Alexandrovich (Богомолец А.А., 1881–1946)

Oleksandr Oleksandrovych Bohomolets was born on 12 (24) May 1881 in Kiev, Russian Empire, and died on 19 July 1946 in the same city, then the Ukrainian SSR. He was elected Academician in 1932 and served as Vice-President of the USSR Academy of Sciences while simultaneously presiding over the National Academy of Sciences of Ukraine from 1930 until his death. The Stalin Prize first class came in 1941, the title Hero of Socialist Labour in 1944.^[3]

He ran an unusual amount of biology for one person. He directed the Bogomoletz Institute of Clinical Physiology in Kyiv, the Moscow Institute of Hematology and Blood Transfusion (now the National Medical Research Center for Hematology), and held positions at Saratov University from 1911 to 1925 and Moscow University from 1925 to 1931; he also set up laboratories at the Georgian Academy of Sciences from 1937 onward. The Bogomolets National Medical University in Kyiv, founded in 1841, was renamed for him after the war.^[4][5]

The work that feeds the bioregulator programme is twofold. First, the **anti-reticular cytotoxic serum** (ACS / АЦС, the "Bogomolets serum"), developed in the 1930s — a heterologous antiserum raised in horses, rabbits, or goats against human spleen and bone marrow, intended in sub-lethal "stimulating" doses to wake up the body's connective-tissue "physiological system."^[6] The *New York Times* covered the American trials on 5 May 1946, weeks before Bogomolets's death.^[7] The 1948 American review by Ilfeld and the 1981 Russian retrospective by Miagkaia established it as the dominant therapeutic innovation of Soviet gerontology in the 1930s–40s.^[8][9] Underneath ACS sat a theory: that connective tissue is not a passive scaffold but a single integrative physiological system governing reactivity, ageing, and resistance to disease. Bogomolets's 1946 English-language book *The Prolongation of Life*, translated by P.V. Karpovich and S. Bleeker for Essential Books (Duell, Sloan & Pearce, New York), is the manifesto. He also convened the first world scientific conference on ageing and longevity in Kyiv in 1938; the proceedings, *Starost'*, ran to 490 pages under his editorship at the UkrSSR Academy of Sciences in 1939.^[10]

Bogomolets supplies four concepts the bioregulator programme inherits verbatim. The **connective-tissue-as-master-regulator** model — the move of treating a single organ system as the lever on systemic ageing — is exactly what Thymalin (thymus), Epithalamin (pineal), and Cortexin (cerebral cortex) do at the peptide level. Moskalev et al. acknowledge in 2023 that "this mechanism is similar to cell therapy, and like the latter, the effectiveness of the Bogomolets method for extending life is not at all obvious," placing ACS as the conceptual ancestor of modern peptide tissue therapy.^[11] Second, the **anti-tissue heterologous serum as a non-specific biostimulator**: ACS was a polyclonal xenogenic antibody directed against an animal organ's structural antigens, used in sub-lethal doses — and Thymalin/Epithalamin/Cortexin/Prostatilen/Retinalamin are its direct linear descendants, reframed as low-dose, tissue-targeted biologicals that activate host repair pathways. Third, the **gerontology-as-state-project** template: Bogomolets secured Stalin's personal backing for life-extension research (per Roy Medvedev's *The Unknown Stalin*, 2005); Khavinson operated inside the same state apparatus, first via the Ministry of Defence, then via the USSR/Russian Academy of Medical Sciences. Fourth, the **cytotoxin → monoclonal-antibody → peptide-fraction** chain: Ilfeld's 1948 review, Aleksieieva's 120th-anniversary retrospective in 2001, and Cordaro's 1951 *Minerva Medica* survey trace ACS into cytotoxic sera, into monoclonals, and — by implication — into the modern tissue-specific peptide preparations such as Khavinson's.^[12][13] Stambler's 2014 *History of Life-Extensionism* calls Bogomolets "the 'Captain Ahab' of Soviet gerontologists" and threads him, Filatov, and Tushnov into a single chain feeding modern Russian gerontology.^[14]

The collected *Izbrannye trudy* — Bogomolets's selected works in three volumes, published by the Academy of Sciences of the Ukrainian SSR between 1956 and 1958 (Vol. I, 1956, 284 pp.; Vol. II, 1957, 480 pp.; Vol. III, 1958, 360 pp.) — is the standard scholarly record of the Bogomolets corpus (bibliography detailed in Nigmatullin & Mukhametova 2022, above).

2. Bulata P.I. (Булат П.И.) — early Soviet organotherapy

This entry is necessarily the shortest. The bibliographic trail on Bulata as a *physician-organotherapist* is fragmentary — the standard Russian pharmaceutical reference works cite him as co-author of early Soviet organotherapy texts, but no single biographical monograph anchors him the way the others on this list are anchored. (Note: a Lev Petrovich Bulat shows up on Wikipedia as a *physicist* in semiconductor physics, and he is a different person; do not confuse them.) Treat the entry, then, as an index of an early Soviet organotherapy school rather than a single attributed monograph.

That school occupied the clinical-pharmacology and veterinary-medicine networks of the 1930s–40s, and its production was the systematisation of *органопрепараты* — animal-organ-derived therapeutic preparations. It runs parallel to Filatov's placenta-extract work and is older than it. Two intellectual debts survive. First, the **organ-homologous biogenic-substance principle**: the doctrine that every organ contains specific "biogenic" substances capable of restoring function in the homologous human organ. The European precursor is Charles-Édouard Brown-Séquard's 1889 testicular-extract work in Vienna. Second, the **industrial tissue-extraction methodology** — cold, aseptic processing of animal organs — that Filatov's biogenic-stimulators school inherited and that Khavinson's Thymalin/Epithalamin/Prostatilen production chain ultimately industrialised.^[15][16]

Bulata/organotherapy is, accordingly, the oldest Soviet doctrine Khavinson inherits: *organ-homologous biogenic extract as therapy*. The same founding assumption — that an extract of an animal organ contains regulators useful for the corresponding human organ — sits underneath Thymalin (thymus extract → immunity), Epithalamin (pineal extract → melatonin / ageing axis), Cortexin (cortex extract → brain), Prostatilen (prostate extract → prostate), and Retinalamin (retinal extract → retina). Khavinson's move from organotherapy to *peptide* bioregulators is a purification of this older doctrine: he isolates the peptide fraction, and then the active short peptide within it.

The Rhythmus portal's essay on potentiated organopreparats, the Med-info overview on organotherapy treatment, and the bibliographic record in Nigmatullin & Mukhametova 2022 fill in the secondary literature.^[17][18]

3. Filatov, Vladimir Petrovich (Филатов В.П., 1875–1956)

Volodymyr Petrovych Filatov was born on 15 (27) February 1875 in Mikhailovka, Penza Governorate (now Mordovia), and died on 30 October 1956 in Odessa. He was an Academician of the USSR Academy of Medical Sciences and a pupil of V.F. Voino-Yasenetsky; he worked in Odessa from 1903. He founded the Ukrainian Institute of Experimental Ophthalmology in 1936 — renamed the Filatov Institute of Eye Diseases and Tissue Therapy after his death — and ran it for the rest of his life at Odessa State Medical University.^[19][20][21]

Filatov did two things at world-class level. The first was corneal transplantation: the first successful operation was on 6 May 1931, and the tube-flap grafting technique he developed set the standard for preserved-cadaver-cornea surgery for a generation. The second was **tissue therapy** (*тканевая терапия*) and the **doctrine of biogenic stimulators**, formulated in 1933 and expanded through the 1942–1953 period. The hypothesis: when a living tissue is exposed to unfavourable but non-lethal conditions — cold, darkness — it produces "biogenic stimulators," non-specific resistance factors that, when injected or implanted into another organism, activate the host's general protective and reparative systems. The 1951 *Izvestiya AN SSSR* paper with Starshinov, "Filatov-Starshinov doctrine of biogenic stimulators," generalised the principle: these substances are "formed everywhere there is a struggle for life and adaptation to new conditions of existence."^[22] Filatov produced four cold-conserved tissue preparations in his lifetime — *extractum aloes*, *peloidodistillate*, *FiBS*, and *extractum placentae* — all crude polypeptide-rich extracts, all mass-produced at the Filatov Institute from 1953 onward.^[23]

Filatov's biogenic-stimulators doctrine is the *conceptual template* of the Khavinson programme, and the link is direct in three places. First, the **material chain**: the placenta extract (*экстракт плаценты по Филатову*) became a standard Soviet preparation; Thymalin (1970s) and Epithalamin (1970s) are its purified successors — they isolate the peptide fraction from exactly this class of tissue preparation. As Condor Research summarises: "In the Soviet era, researchers began isolating tissue extracts … From the thymus came a preparation called Thymalin, studied for immune function; from the pineal gland came Epithalamin."^[24] Second, the **methodological inheritance**: Filatov's industrial pipeline — cold storage at 2–4 °C in the absence of light, extraction, sterile ampouling — is reproduced almost step-for-step in the Thymalin/Epithalamin production specifications at the St. Petersburg Institute of Bioregulation and Gerontology. Third, the **placenta-extract thread** ("Filatov → Korsakov → Khavinson"): the placental extract became a standard Soviet/Russian preparation; Korsakov and others in the Odessa school developed placental hydrolysates (Polyamine and others) in the 1950s–70s; these fed into the broader Russian tissue-extract tradition from which Khavinson drew, and the contemporary Khavinson-school products Cortagen, Prostatilen, and Retinalamin are direct phylogenetic descendants of the Filatov placenta-extract idea applied to other organs. Stambler (2014) groups Filatov, Tushnov, and Bogomolets as the three Soviet "regenerative autocatalysis" theorists whose shared principle — "rejuvenative and regenerative autocatalysis" — feeds into modern Russian anti-ageing biology.^[14]

Filatov's monographs are the documentary spine of the school: *Тканевая терапия* (Tashkent, 1943); *Оптическая пересадка роговицы и тканевая терапия* (Moscow, 1945); the Ukrainian edition *Оптична пересадка рівки і тканинна терапія* (Kyiv: DMV, 1948, 382 pp.); and the consolidated *Тканевая терапия. Биогенные стимуляторы. Пересадка роговицы* (Kyiv, 1953, 307 pp.). The 1993 *British Journal of Ophthalmology* obituary by Korik and the 1970 *JAMA Ophthalmology* obituary by Kornilovsky remain the standard English-language biographical notices.^[25][26] Diброва's 2023 CyberLeninka memorial essay, the RHANA historical clinical archive on tissue-therapy practice in the USSR, the Placentarium research portal's survey of Soviet placental research, and the Mail.ru science overview on the arc from Filatov to cell technologies complete the secondary literature.^{[27][28][29][30]} The Filatov Institute's own repository hosts the canonical "Учение В.П. Филатова о биогенных стимуляторах" lecture.^[31]

4. Pavlov, Ivan Petrovich (Павлов И.П., 1849–1936) — nervism doctrine

Ivan Petrovich Pavlov was born on 14 (26) September 1849 in Ryazan and died on 27 February 1936 in Leningrad. He received the 1904 Nobel Prize in Physiology or Medicine for his work on digestion.^[32][33]

The biographical fact that matters most for this genealogy is institutional. Pavlov worked and lectured at the S.M. Kirov Military Medical Academy in Leningrad from the 1870s — the same building where Khavinson would train as a military physician in the 1960s and 70s and return to run a laboratory in the 1980s. Pavlov also directed work at the Institute of Experimental Medicine, Leningrad. In the 2013 Rattan interview, Khavinson identifies Pavlov's lecture-hall at the Academy as a formative environment and explicitly calls himself "a grand-student of I.P. Pavlov."^[2]

Pavlov's substantive contribution that filters into the bioregulator programme is **nervism** (*нервизм*) — the doctrine that the nervous system governs and integrates the activity of all organs, including in pathology. His first independent monograph, the 1883 *Die zentrifugalen Nerven des Herzens* (St. Petersburg), introduced the *intensifying* (trophic) nerve concept: the idea that nerves exert a *trophic*, regulating influence on tissue metabolism, not merely a triggering or excitatory one. The conditioned-reflex work with I.F. Tolochinov (1901) and *Twenty Years of Objective Study of the Higher Nervous Activity (Behaviour) of Animals* sit alongside that trophic-innervation doctrine as the canonical Pavlovian corpus. The 1999 CyberLeninka paper by Zabrodin, "Проблема нервной трофики в трудах И.П. Павлова и его школы," and the 2005 Springer paper by Akimov that cites Pavlov's "On Trophic Innervation" trace the lineage.^[34][35]

Pavlov is the *intellectual grandfather* of Soviet tissue therapy, not a direct biochemical ancestor. The links run four ways. First, the **Kirov Military Medical Academy lineage** — Khavinson's training and laboratory were inside Pavlov's institutional home.^[2] Second, **nervism → trophism → tissue extracts**: Pavlov's trophic-innervation doctrine (nerves regulate tissue metabolism, not only behaviour) licensed Speransky's neurodystrophic process theory (§5) and Bogomolets' reactivity-of-the-organism theory (§1); Khavinson's mechanism — that a peptide fraction extracted from one organ exerts a "tissue-specific regulatory effect" — is the molecular descendant of trophic innervation. Just as Pavlov saw nerves as carrying trophic information to tissues, Khavinson sees short peptides as carrying regulatory information to tissues. Third, the **1950 Pavlovian Session**: the Joint Session of the USSR Academy of Sciences and Academy of Medical Sciences in June–July 1950 elevated Pavlovian nervism to state orthodoxy and mandated that all Soviet physiology be brought into line with it. The rise of tissue therapy, organotherapy, and biogenic-stimulator research in the 1950s USSR — including the establishment of the tissue-therapy production plant in Odessa and the Morozov–Khavinson peptide work at the Military Medical Academy — happened inside this Pavlovian ideological frame.^[36] The 2022 Reutov et al. paper in *PMC 9762671* traces nervism and Pavlov into modern Soviet/Russian neuroscience.^[37] Fourth, the **higher-nervous-activity doctrine as a framing for psychosomatic ageing**: Khavinson's later work (1973–2013) repeatedly cites the integrative "stress-resistance" model the Pavlovian school endorsed, and his Epithalamin mechanism (pineal → melatonin → neuroendocrine axis) reads as a Pavlovian-style "nervous-system-master regulator" model rendered in molecular terms.

The standard English-language reference for the biographical sweep is Britannica's Pavlov entry and the Colorado State University HiPath historical lecture.^[38][39]

5. Speransky, Alexei Dmitrievich (Сперанский А.Д., 1888–1961)

Aleksei Dmitrievich Speransky was born on 30 December 1887 (12 January 1888 New Style) in Moscow and died on 28 July 1961 in Moscow. He became an Academician in 1939 and won the Stalin Prize in both 1941 and 1952.^[40][41][42]

He studied medicine with honours at Kazan University and then moved to Leningrad's All-Union Institute of Experimental Medicine (VIEM), where he worked with Pavlov's blessing. From 1926 he ran the experimental department of the Institute for Surgical Neuropathology, and he later directed the Moscow Institute of General and Experimental Pathology.^[43] In the wartime years the institute was evacuated; the NIIOPP retrospective on "Academician Speransky in the years of the Great Patriotic War" preserves that record.^[44]

The substantive contribution is the **theory of the neurodystrophic process** (*нейродистрофический процесс*). The doctrine: the nervous system initiates a *standardised* chain of destructive tissue changes — "nervous dystrophies" — in response to *any* sufficiently strong peripheral irritation, regardless of the nature of the irritant. The change is neurogenic rather than tissue-autonomous; the tissue is, in a sense, an output device of the nerve signal.^[45][46] Speransky's signature demonstration was the "second-hit" experiment: a second, distant noxious stimulus (e.g., puncture of the second cerebral hemisphere in a dog that had recovered from a first hit) could reactivate or amplify the original neurodystrophic process — the methodological foundation of neural therapy (the Huneke phenomenon) and of modern stress-axis neuroimmunology. The synthesis volume is *A Basis for the Theory of Medicine* (Moscow-Leningrad, 1937; English translation, International Publishers, New York, 1943).^[47]

Speransky supplies the *patho-physiological mechanism* that the bioregulator programme presupposes. First, the **neurodystrophic process as the substrate of chronic degenerative disease**: Speransky argued that chronic, non-specific tissue degeneration is *neurogenic* in origin. Filatov's biogenic stimulators (§3) and Bogomolets' anti-reticular cytotoxic serum (§1) are best understood as attempts to interrupt or replace the neurodystrophic process with a non-specific exogenous stimulus. Khavinson's peptide bioregulators inherit this assumption: short peptides are the molecular signals that re-set tissue regulation at a level below the neurogenic dystrophic cascade. Second, the **distant-trophic regulatory effect**: Speransky demonstrated that a small local intervention can have a systemic trophic effect (his punctate-hit experiments); this is the experimental predecessor of the modern Russian claim — central to Khavinson's Epithalamin/Thymalin/Cortexin evidence base — that a subcutaneous injection of a peptide fraction produces a measurable, systemic, longevity-relevant effect.^[48] Third, **continuity with Pavlov**: Speransky was Pavlov's student and explicitly framed his neurodystrophic theory as a Pavlovian nervism project. The Pavlov → Speransky → Bogomolets → Khavinson chain is a single lineage of increasingly molecular explanations for nervous-system-mediated systemic regulation.

The standard Russian-language reference for the biographical and bibliographical record is the 1971 *Kazan Medical Journal* obituary by Kartashov.^[49] Speransky's own monographs anchor the corpus: *Нервная система в патологии* (1930), the edited *Нервная трофика в теории и практике медицины* (VIEM, 1936), *Элементы построения теории медицины* (1937), and the posthumous *Нервная трофика в физиологии и патологии* (1970). The RAS publication page on Speransky and the Studfile lecture text on the neurodystrophic process complete the documentary record.^[50]

6. Asatiani, Georgy Iraklievich (Асатиани Г.И., 1914–?)

Georgy Iraklievich Asatiani was born on 28 May (10 June) 1914 in Borzia, Chita Oblast, Russian Empire.^[51] The Big Soviet Encyclopedia (3rd ed., vol. 2) entry records him as a Soviet scientist in the tissue-therapy field.^[52]

A caveat that any reader of the Russian organotherapy literature needs to know: a 1957 monograph on tissue therapy is sometimes attributed to a "G.S. Asatiani" in the secondary literature — that should be cross-checked against the BSE record, which lists Georgy Iraklievich Asatiani (born 1914, Borzia) as the relevant scholar. He is distinct from **Vladimir Samsonovich Asatiani** (V.S. Asatiani), a Georgian biochemist at Tbilisi whose *Новые методы биохимической фотометрии* (Nauka, Moscow 1965, 542 pp.; 2nd ed., 1972, 302 pp.) is the canonical Soviet biochemical-photometry reference work. The two are not the same person; the bibliography below lists both where relevant.

G.I. Asatiani worked at the Institute of General Pathology and Pathological Physiology — associated with Bogomolets' school — and was active in the late Stalin and Khrushchev tissue-therapy research network that grew out of the Filatov/Bogomolets work. V.S. Asatiani was at the Georgian Academy of Sciences in Tbilisi.^[53] G.I. Asatiani's main contribution is the synthesis review of Soviet tissue-therapy literature in the mid-1950s — the Filatov placenta-extract programme, the Bogomolets cytotoxin/connective-tissue system, and the early organotherapy school — consolidated into a unified bibliographic and methodological whole. The 1960 *Журнальная летопись* paper by Rakhmetov on tissue-therapy effects on rabbit-blood morphology, G.I. Asatiani's citations in Shklyar's 1995 biorhythmology monograph, the disserCat reproductive-system epithelial tissue dissertation that cites Asatiani, the BSE 3rd-ed. record, and the 1955 veterinary tissue-therapy paper "Тканевая терапия коров при гинекологических заболеваниях" all bear on his bibliography.^[54][55][56]

Asatiani represents the **mid-century consolidation** of the Soviet tissue-therapy programme into a standard reference corpus, just as Khavinson's generation was taking it over. His monograph was the canonical 1957 synthesis of what had been learned about tissue therapy in the 1950s; Khavinson's 1970s peptide-extract work is downstream of this consolidation, treating the Filatov/Bogomolets/Asatiani corpus as established science and re-engineering its active fraction. V.S. Asatiani's *Новые методы биохимической фотометрии* became the standard analytical reference for Soviet tissue-extract characterisation in the 1960s–80s — the analytical machinery Khavinson used to standardise the Thymalin/Epithalamin polypeptide fractions; the RU2240123C1 patent "Экзогенные биологически активные…" cites Asatiani directly in its standardisation section.^[57] G.I. Asatiani is also the **bridge figure** between the Filatov/Bogomolets generation and the St. Petersburg school — his mid-century synthesis is the last major published reconciliation of the tissue-therapy school before the bioregulator reframing of the 1970s–80s.

7. The contested "Kuhn / Sandor 1920s German school" of endogenous bioregulators

A note of caution to lead with. The "cascade theory of peptide regulation of ageing" — and the citation to a 1920s German school of endogenous bioregulators that usually accompanies it — is one of the standard critique points in Western readings of the Khavinson literature. Stambler (2014) and others have flagged it as anachronistic. This entry is, accordingly, short on assertions and long on footnoting the contestation.

The attribution usually runs to two figures. **Richard Kuhn** (1900–1967), Nobel Chemistry 1938, Heidelberg / Kaiser Wilhelm Institute for Medical Research — identified and characterised several biologically-active peptides and small molecules in the 1920s–30s (B-vitamin work, carotenoids, etc.). The "endogenous bioregulator" reading of Kuhn's work is anachronistic: Kuhn did not propose a "bioregulator cascade." His primary publication record sits in *Hoppe-Seyler's Zeitschrift für physiologische Chemie* and the *Berichte der deutschen chemischen Gesellschaft*. **Imre (Emmerich) Sándor** — a Budapest-born endocrinologist working in the 1920s–30s in Berlin and Budapest private laboratories — proposed that soluble tissue extracts contain "bioregulator" substances that maintain endocrine homeostasis. This is the doctrinal seed later rebranded by the Khavinson school as the "peptide bioregulator cascade." Sándor's publication record is fragmentary; bibliographic completeness for his European endocrinology articles is limited. Both figures are peripheral to modern mainstream peptide endocrinology.

The link to Khavinson is **contested**, and the chain runs three ways. First, the Khavinson school uses "cascade" terminology — a 1→2→3→… amplification step from peptide signal to gene regulation to tissue phenotype — borrowed from biochemistry (the coagulation cascade, the complement cascade, the kinase cascade). This is internal to the 1990s–2000s Russian gerontology literature. Second, citations to "Kuhn" and "Sandor" appear in Khavinson-group papers and reviews as the historical antecedents of the bioregulator concept; independent verification of this attribution is weak. The lineage is best treated as a *desirable ancestral claim* rather than a documented one — the Khavinson school has obvious incentive to cite a pre-WWII European pedigree, but the documentary evidence is thin. Third, the substantive content of "cascade theory of peptide regulation of ageing" is a 1970s–80s Russian formulation; it does not derive from Kuhn or Sándor except by retrospective citation. As Longevitix (2026) puts it, "most of the in vitro work that has appeared in Western journals carries Khavinson group co-authorship," and Sparta Labs (2026) notes that "the analytical identification of the AEDG tetrapeptide within that complex was reported only in 2017."

**Honest assessment.** This entry should be read as a "claimed but weakly documented" lineage. The real genealogy of the Khavinson peptide doctrine runs Bogomolets → Filatov → Pavlov/Speransky → Asatiani's mid-century synthesis → Khavinson's own 1970s pefaction of the Filatov biogenic-stimulators programme. The Kuhn/Sandor citation is the only significant Western-precedent claim that should be treated as more aspirational than documented.

Summary genealogy (one-page diagram)

Pavlov (nervism / trophic innervation)
        │
        ├── Speransky (neurodystrophic process)
        │         │
        │         └── Bogomolets (connective-tissue physiology, ACS / АЦС,
        │                            life-extension, gerontology as state
        │                            project)
        │                │
        │                ├── Filatov (biogenic stimulators doctrine,
        │                │            placenta extract, tissue therapy)
        │                │       │
        │                │       └── Asatiani G.I. (1957 monograph
        │                │            consolidating the tissue-therapy
        │                │            school; V.S. Asatiani biochemical-
        │                │            photometric standardisation, 1965)
        │                │
        │                └── Bulata / Soviet organotherapy school
        │                            (organ-homologous biogenic extracts)
        │                            │
        │                            └── (all of the above feed into)
        │                                    │
        │                                    ▼
        │                          Khavinson + Morozov (1971–2013)
        │                          — peptide extraction at the Kirov
        │                            Military Medical Academy →
        │                          Thymalin / Epithalamin (1970s)
        │                            → Cortexin, Prostatilen,
        │                              Retinalamin
        │                            → synthetic short peptides
        │                              (Epitalon/AEDG, Vilon,
        │                               Cortagen, Pinealon,
        │                               Livagen, Vesugen, etc.)
        │                            → "peptide bioregulator"
        │                              geroprotector doctrine
        │
        └── [Contested]
              Kuhn / Sandor (1920s German "endogenous bioregulator"
              school) — cited by Khavinson school as a Western
              pedigree; independent verification weak.

What Khavinson actually inherited, distilled